Coya Therapeutics and Dr Reddy's link up on ALS research

Texas, USA-based Coya Therapeutics (Nasdaq: COYA) saw its shares rise 2.5% to $7.46, on news of deal with India’s Dr Reddy’s Laboratories (BSE: 500124) on the development and license agreement for the development and commercialization of COYA-302, an investigational combination therapy for the treatment of amyotrophic lateral sclerosis (ALS).

Coya has granted Dr Reddy’s an exclusive license to commercialize COYA-302, a proprietary co-pack kit containing combination of low dose interleukin (IL)-2 and CTLA-4 Ig (abatacept) in the USA, Canada, the European Union and the UK for ALS. This agreement is in addition to the in-licensing agreement with Dr Reddy’s signed in early 2023.

Coya retains the right to commercialize COYA-302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each country in South America. Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA-302 for patients with ALS in the USA.